Entera Bio Ltd (ENTX)
NASDAQ:ENTX
Want to see ENTX full AI Analyst Report?
Top Page
Entera Bio
(NASDAQ:ENTX)
Select Model
Select Model
Rating:49Neutral
Price Target:
$1.00
▼(-21.88% Downside)
Action:Reiterated
Date:05/09/26
The score is held back primarily by weak financial performance (no revenue and significant cash burn), partially offset by a low-debt balance sheet. Technicals are mildly improving in the short term but remain weak on longer-term moving averages. Corporate events are a net positive due to Phase 3 progress and added funding, while valuation signals are less decisive given the company’s loss-making, pre-commercial profile.
Positive Factors
Regulatory path acceleration (EB613)
A streamlined Phase 3 via a 505(b)(2) reference to Forteo and a single‑tablet “Next‑Gen” formulation shortens timelines and trial size (≈750 patients, 12‑month hip BMD primary). This structurally improves probability of efficient registration and later commercial adoption versus longer, larger trials.
Negative Factors
Pre-commercial revenue profile
With no meaningful commercial revenue and persistent net losses, the company lacks internally generated funding to progress multiple clinical programs. This structural dependence on external capital creates execution risk over the coming 2–6 months as programs advance toward costlier phase‑3 activities.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory path acceleration (EB613)
A streamlined Phase 3 via a 505(b)(2) reference to Forteo and a single‑tablet “Next‑Gen” formulation shortens timelines and trial size (≈750 patients, 12‑month hip BMD primary). This structurally improves probability of efficient registration and later commercial adoption versus longer, larger trials.
Read all positive factors
Entera Bio (ENTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$60.55M
Dividend YieldN/A
Average Volume (3M)123.78K
Price to Earnings (P/E)―
Beta (1Y)0.45
Revenue Growth-100.00%
EPS Growth-2.09%
CountryUS
Employees18
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.12
Shares Outstanding49,225,323
10 Day Avg. Volume240,874
30 Day Avg. Volume123,776
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)6.84
Price to Sales (P/S)2133.59
P/FCF Ratio-11.98
Enterprise Value/Market Cap0.95
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.82K
Enterprise Value/Ebitda-4.62
Forecast
1Y Price Target
$9.00Price Target Upside603.13% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.42
Revenue Forecast (FY)$54.58M
Entera Bio Business Overview & Revenue Model
Company Description
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which i...
How the Company Makes Money
Entera Bio’s revenue model is primarily not based on product sales because it is a clinical-stage company and, to the extent publicly available information indicates, it does not have broadly commercialized products generating recurring commercial...
Entera Bio Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
64
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 42.00K | 181.00K | 0.00 | 134.00K | 571.00K |
| Gross Profit | -15.00K | 0.00 | 9.00K | -56.00K | -31.00K | 198.00K |
| EBITDA | -12.42M | -11.50M | -9.54M | -8.80M | -12.87M | -12.16M |
| Net Income | -12.38M | -11.44M | -9.54M | -8.89M | -13.07M | -12.19M |
Balance Sheet | ||||||
| Total Assets | 13.13M | 15.99M | 9.39M | 11.77M | 13.13M | 25.99M |
| Cash, Cash Equivalents and Short-Term Investments | 4.14M | 7.11M | 8.66M | 11.02M | 12.31M | 24.89M |
| Total Debt | 448.00K | 490.00K | 272.00K | 390.00K | 91.00K | 302.00K |
| Total Liabilities | 2.44M | 2.89M | 1.31M | 1.38M | 1.37M | 3.42M |
| Stockholders Equity | 10.69M | 13.10M | 8.08M | 10.39M | 11.75M | 22.57M |
Cash Flow | ||||||
| Free Cash Flow | -9.61M | -7.48M | -6.82M | -7.33M | -12.55M | -9.08M |
| Operating Cash Flow | -9.50M | -7.37M | -6.82M | -7.31M | -12.50M | -9.06M |
| Investing Cash Flow | -105.48K | -107.00K | -3.00K | -17.00K | -102.00K | -17.00K |
| Financing Cash Flow | 1.33M | 13.71M | 4.48M | 6.04M | 13.00K | 25.38M |
Entera Bio Technical Analysis
Positive
1.28
Price Trends
1.21
Positive
1.36
Negative
1.77
Negative
Market Momentum
0.02
Negative
52.91
Neutral
52.37
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ENTX, the sentiment is Positive. The current price of 1.28 is above the 20-day moving average (MA) of 1.21, above the 50-day MA of 1.21, and below the 200-day MA of 1.77, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 52.91 is Neutral, neither overbought nor oversold. The STOCH value of 52.37 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ENTX.
Entera Bio Risk Analysis
Entera Bio disclosed 2 risk factors in its most recent earnings report. Entera Bio reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
Security, political and economic instability in the Middle East may harm our business. Q1, 2026
Entera Bio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $112.85M | -12.04 | 111.73% | ― | ― | 36.33% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $60.55M | -3.78 | -87.97% | ― | -100.00% | -2.09% | |
45 Neutral | $116.34M | -9.06 | -61.43% | ― | -100.00% | 18.25% | |
44 Neutral | $50.94M | -1.77 | -99.87% | ― | ― | 8.93% | |
44 Neutral | $73.07M | -0.97 | -59.06% | ― | ― | 49.00% |
* Healthcare Sector Average
ENTX
Entera Bio
1.27
-0.64
-33.51%
ATYR
aTyr Pharma
0.53
-3.22
-85.87%
NRXP
NRX Pharmaceuticals
3.03
0.40
15.21%
EQ
Equillium
1.77
1.38
358.44%
PLRX
Pliant Therapeutics
1.15
-0.18
-13.53%
Entera Bio Corporate Events
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresPrivate Placements and FinancingRegulatory Filings and Compliance
Entera Bio Highlights Q1 2026 Progress and Financing
Positive
May 8, 2026
Entera Bio reported first-quarter 2026 results on May 8, 2026, highlighting progress across its oral peptide pipeline, led by EB613, an oral anabolic tablet for postmenopausal osteoporosis. In March 2026 the company submitted a streamlined Phase 3...
Business Operations and StrategyPrivate Placements and Financing
Entera Bio Announces $10 Million Private Placement Financing
Positive
Apr 3, 2026
On April 1, 2026, Entera Bio entered into a Securities Purchase Agreement with funds affiliated with BVF Partners LP for a $10 million private placement of 7,827,789 units, each comprising ordinary shares or pre-funded warrants and accompanying or...
Business Operations and StrategyFinancial Disclosures
Entera Bio Reports 2025 Results, Advances Oral Osteoporosis Pipeline
Positive
Mar 27, 2026
Entera Bio reported its full-year 2025 results on March 27, 2026, highlighting progress on EB613, its lead oral anabolic osteoporosis therapy, and alignment with the FDA on using total hip bone mineral density as a primary Phase 3 endpoint. The co...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Entera Bio Submits Streamlined Phase 3 Plan for EB613
Positive
Mar 4, 2026
Entera Bio announced on March 4, 2026, that it has submitted a streamlined Phase 3 protocol, statistical analysis plan and extension-study synopsis to the U.S. Food and Drug Administration for EB613, its oral teriparatide tablet for postmenopausal...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.